MannKind Corp (MNKD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:MannKind Corp (MNKD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014271
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MannKind Corp (MannKind) is a biopharmaceutical company that discovers, develops and commercializes therapeutic products to treat diseases such as diabetes. The company’s lead product, Afrezza is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It also developed a line of breath-powered, dry powder inhalers. Mannkind develops its products based on Technosphere drug delivery platform, its proprietary formulation technology. It also utilizes inhalation profiling technologies such as BluHale. It conducts its manufacturing operations in Danbury, Connecticut and sells its products in the US through a direct sales force. MannKind is headquartered in California, the US.

MannKind Corp (MNKD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MannKind Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MannKind and Biomm Enter into Distribution Agreement 12
MannKind Partners with JDRF 13
Licensing Agreements 14
Receptor Life Sciences Enters into Licensing Agreement with MannKind 14
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 15
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 17
Equity Offering 18
Mannkind to Raise USD61 Million in Private Placement of Shares 18
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 20
MannKind Raises USD36.2 Million in Private Placement of Shares 21
Mannkind Raises USD50 Million in Private Placment of Shares 22
MannKind Announces Public Offering Of Common Stock For US$50 Million 24
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 25
MannKind Completes Public Offering Of Units For US$86 Million 27
Debt Offering 29
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 29
MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For US$370 Million 31
MannKind Corp – Key Competitors 32
MannKind Corp – Key Employees 33
MannKind Corp – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Nov 07, 2017: MannKind Reports 2017 Third Quarter Financial Results 35
Aug 07, 2017: MannKind Reports 2017 Second Quarter Financial Results 37
May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 39
Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 40
Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results 42
Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results 44
May 09, 2016: MannKind Reports 2016 First Quarter Financial Results 45
Mar 14, 2016: MannKind Reports 2015 Fourth Quarter and Full Year Financial Results 46
Corporate Communications 47
Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 47
Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 48
Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 49
Feb 19, 2016: Alfred Mann Steps Down as Executive Chairman of Mannkind 50
Jan 11, 2016: MannKind Provides Update on Senior Management 51
Product News 52
08/01/2016: Mannkind Assumes Responsibility for Distribution of Afrezza and Launches Patient Reimbursement and Adherence Support Programs 52
06/12/2016: MannKind Announces Late-Breaking Data Demonstrating Faster Onset and Shorter Duration of Action Compared to Mealtime Insulins 53
Mar 08, 2017: MannKind and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes 55
02/01/2017: MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth 56
Other Significant Developments 57
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
MannKind Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MannKind Corp, Deals By Therapy Area, 2011 to YTD 2017 9
MannKind Corp, Medical Devices Deals, 2011 to YTD 2017 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MannKind and Biomm Enter into Distribution Agreement 12
MannKind Partners with JDRF 13
Receptor Life Sciences Enters into Licensing Agreement with MannKind 14
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 15
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 17
Mannkind to Raise USD61 Million in Private Placement of Shares 18
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 20
MannKind Raises USD36.2 Million in Private Placement of Shares 21
Mannkind Raises USD50 Million in Private Placment of Shares 22
MannKind Announces Public Offering Of Common Stock For US$50 Million 24
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 25
MannKind Completes Public Offering Of Units For US$86 Million 27
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 29
MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For US$370 Million 31
MannKind Corp, Key Competitors 32
MannKind Corp, Key Employees 33
MannKind Corp, Other Locations 34

★海外企業調査レポート[MannKind Corp (MNKD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Capital Lease Aviation Limited:企業の戦略・SWOT・財務分析
    Capital Lease Aviation Limited - Strategy, SWOT and Corporate Finance Report Summary Capital Lease Aviation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Future Consumer Ltd (FCONSUMER):企業の財務・戦略的SWOT分析
    Future Consumer Ltd (FCONSUMER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Biosensors International Group Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Biosensors International Group Ltd (Biosensors) is a medical devices company. It develops, manufactures and markets medical devices. The company products find application in Interventional cardiology and critical care procedures. The company classifies its products into four categories: Inte …
  • Orix Corporation:企業の戦略・SWOT・財務分析
    Orix Corporation - Strategy, SWOT and Corporate Finance Report Summary Orix Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Genera Biosystems Ltd (GBI):企業の財務・戦略的SWOT分析
    Summary Genera Biosystems Ltd (GBL) is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is …
  • Gordon Ramsay Holdings Limited:企業の戦略・SWOT・財務情報
    Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • TIVIT Terceirizacao de Tecnologia e Servicos SA:企業の戦略的SWOT分析
    TIVIT Terceirizacao de Tecnologia e Servicos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Faron Pharmaceuticals Oy (FARN):医療機器:M&Aディール及び事業提携情報
    Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that conducts clinical stage drug discovery and development. The company's pipeline products focus on cute organ traumas, vascular damage and cancer immunotherapy. It offers Traumakine, that helps to prevent vascu …
  • Austrian Airlines AG:企業の戦略・SWOT・財務情報
    Austrian Airlines AG - Strategy, SWOT and Corporate Finance Report Summary Austrian Airlines AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Yandex NV (YNDX):企業の財務・戦略的SWOT分析
    Yandex NV (YNDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Exxon Mobil Corporation (XOM)-エネルギー分野:企業M&A・提携分析
    Summary Exxon Mobil Corporation (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. It is a major manufactu …
  • Chr. Hansen Holding AS (CHR):製薬・医療:M&Aディール及び事業提携情報
    Summary Chr. Hansen Holding A/S (Chr. Hansen) is a bioscience company that focuses on the development of natural ingredient solutions for the food, pharmaceutical, nutritional and agricultural industries. The company develops, produces and markets cultures, enzymes, probiotics and natural colors. It …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066):企業の財務・戦略的SWOT分析
    Shandong Weigao Group Medical Polymer Company Ltd (1066) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company …
  • Agilent Technologies Inc (A):企業の財務・戦略的SWOT分析
    Agilent Technologies Inc (A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Busan Bank Co., Ltd.:企業の戦略・SWOT・財務情報
    Busan Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Busan Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Hallador Energy Co (HNRG):企業の財務・戦略的SWOT分析
    Hallador Energy Co (HNRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Mitsubishi Gas Chemical Co Inc (4182):企業の財務・戦略的SWOT分析
    Mitsubishi Gas Chemical Co Inc (4182) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Axikin Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Axikin Pharmaceuticals Inc (Axikin) is a biopharmaceutical company that develops small molecule therapeutics for respiratory disorders. The company offers pre-clinical and research programs with small molecule therapeutics for applications in asthma, chronic obstructive pulmonary disease, in …
  • Febo Beheer BV:企業の戦略・SWOT・財務情報
    Febo Beheer BV - Strategy, SWOT and Corporate Finance Report Summary Febo Beheer BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Fluor Corp (FLR):電力:M&Aディール及び事業提携情報
    Summary Fluor Corp (Fluor) is a provider of engineering and construction services. The company's service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. Fluor also offers other services t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆